Ketamine-induced vesicopathy;Ketamininduzierte Vesikopathie

Psychiatrische Praxis

Volumn 39, Issue 1, 2012, Pages 43-45

  Lieb, Martin ^a   Bader, Markus ^b   Palm, Ulrich ^a   Stief, Christiang ^b   Baghai, Thomasc ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

ketamine; vesicopathy

Indexed keywords

BOTULINUM TOXIN A; KETAMINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYSTITIS; HUMAN; MALE; SYMPTOM; TREATMENT REFUSAL; URINARY DYSFUNCTION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVESICAL; ADULT; ANALGESICS; BOTULINUM TOXINS, TYPE A; CYSTECTOMY; CYSTITIS; HIV SEROPOSITIVITY; HUMANS; KETAMINE; MALE; PATIENT COMPLIANCE; SUBSTANCE-RELATED DISORDERS; URINARY DIVERSION; URINATION DISORDERS;

EID: 84855512309     PISSN: 03034259     EISSN: 14390876     Source Type: Journal    
DOI: 10.1055/s-0031-1292789     Document Type: Article

References (21)

1. Noppers I, Niesters M, Aarts L et al. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother: 2010; 11 2417 2429
2. Machado-Vieira R, Salvadore G, Diazgranados N et al. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther: 2009; 123 143 150
3. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol: 2008; 182 313 333
4. Amt fr Verffentlichungen der Europischen Union Kapitel 8: Neue Drogen und sich abzeichnende Tendenzen. In: Amt fr Verffentlichungen der Europischen Union, Hrsg. Europische Beobachtungsstelle fr Drogen und Drogensucht Jahresbericht 2010: Stand der Drogenproblematik in Europa. Luxemburg Amt fr Verffentlichungen der Europischen Union: 2010; 108 115
5. Substance Abuse and Mental Health Services Administration Office of Applied Studies (February 14, 2008). The NSDUH Report Use of Specific Hallucinogens. 2006. Rockville, MD NSDUH: 2008
6. McCambridge J, Winstock A, Hunt N et al. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res: 2007; 13 57 64 (Pubitemid 44973727)
7. Heinz TW. Missbrauch von Ketamin: Neue Modesubstanz der Szene. Dtsch Arztebl: 1999; 96 2724 2726
8. Muetzelfeldt L, Kamboj SK, Rees H et al. Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend: 2008; 95 219 229
9. Chu PS, Ma WK, Wong SC et al. The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int: 2008; 102 1616 1622
10. Shahani R, Streutker C, Dickson B et al. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology: 2007; 69 810 812 (Pubitemid 46670224)
11. Middela S, Pearce I. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract: 2011; 65 27 30
12. Cottrell A, Warren K, Ayres R et al. The relationship of chronic recreational ketamine use and severe bladder pathology: presentation, management of symptoms and public health concerns. Eur Urol Suppl: 2009; 8 170
13. Tsai TH, Cha TL, Lin CM et al. Ketamine-associated bladder dysfunction. Int J Urol: 2009; 16 826 829
14. Neal DE. Interstitial cystitis: evaluation and related conditions. J Urol: 2009; 181 2414 2415
15. Selby NM, Anderson J, Bungay P et al. Obstructive nephropathy and kidney injury associated with ketamine abuse. NDT Plus: 2008; 1 310 312
16. Tsai JH, Tsai KB, Jang MY. Ulcerative cystitis associated with ketamine. Am J Addict: 2008; 17 453
17. Hoskins R. Ketamine associated cystitis a case report. Int Emerg Nurs: 2009; 17 69 71
18. Chen LY, Chen KP, Huang MC. Cystitis associated with chronic ketamine abuse. Psychiatry Clin Neurosci: 2009; 63 591
19. Adeyoju AB, Thornhill J, Lynch T et al. The fate of the defunctioned bladder following supravesical urinary diversion. Br J Urol: 1996; 78 80 83 (Pubitemid 27410420)
20. Singh G, Wilkinson JM, Thomas DG. Supravesical diversion for incontinence: a long-term supravesical diversion for incontinence: a long-term follow-up. Br J Urol: 1997; 79 348 353 (Pubitemid 28318970)
21. Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction: 2009; 104 77 87